Literature DB >> 10473190

Preliminary assessment of extrastriatal dopamine D-2 receptor binding in the rodent and nonhuman primate brains using the high affinity radioligand, 18F-fallypride.

J Mukherjee1, Z Y Yang, T Brown, R Lew, M Wernick, X Ouyang, N Yasillo, C T Chen, R Mintzer, M Cooper.   

Abstract

We have identified the value of 18F-fallypride [(S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2, 3-dimethoxybenzamide], as a dopamine D-2 receptor radiotracer for the study of striatal and extrastriatal receptors. Fallypride exhibits high affinities for D-2 and D-3 subtypes and low affinity for D-4 (3H-spiperone IC50s: D-2 = 0.05 nM [rat striata], D-3 = 0.30 nM [SF9 cell lines, rat recombinant], and D-4 = 240 nM [CHO cell lines, human recombinant]). Biodistribution in the rat brain showed localization of 18F-fallypride in striata and extrastriatal regions such as the frontal cortex, parietal cortex, amygdala, hippocampus, thalamus, and hypothalamus. In vitro autoradiographic studies in sagittal slices of the rat brain showed localization of 18F-fallypride in striatal and several extrastriatal regions, including the medulla. Positron emission tomography (PET) experiments with 18F-fallypride in male rhesus monkeys were carried out in a PET VI scanner. In several PET experiments, apart from the specific binding seen in the striatum, specific binding of 18F-fallypride was also identified in extracellular regions (in a lower brain slice, possibly the thalamus). Specific binding in the extrastriata was, however, significantly lower compared with that observed in the striata of the monkeys (extrastriata/cerebellum = 2, striata/cerebellum = 10). Postmortem analysis of the monkey brain revealed significant 18F-fallypride binding in the striata, whereas binding was also observed in extrastriatal regions such as the thalamus, cortical areas, and brain stem.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10473190     DOI: 10.1016/s0969-8051(99)00012-8

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  46 in total

1.  Characterization of extrastriatal D2 in vivo specific binding of [¹⁸F](N-methyl)benperidol using PET.

Authors:  Sarah A Eisenstein; Jon M Koller; Marilyn Piccirillo; Ana Kim; Jo Ann V Antenor-Dorsey; Tom O Videen; Abraham Z Snyder; Morvarid Karimi; Stephen M Moerlein; Kevin J Black; Joel S Perlmutter; Tamara Hershey
Journal:  Synapse       Date:  2012-05-15       Impact factor: 2.562

2.  Imaging Pancreatic Beta-Cells: Update from the 4th Workshop of the National Institutes of Health, Washington DC, April 2009.

Authors:  Frederic Ris; Lindsey Crowe; Thierry Berney
Journal:  Rev Diabet Stud       Date:  2009-12-30

3.  Cocaine cue-induced dopamine release in the human prefrontal cortex.

Authors:  Michele S Milella; Aryandokht Fotros; Paul Gravel; Kevin F Casey; Kevin Larcher; Jeroen A J Verhaeghe; Sylvia M L Cox; Andrew J Reader; Alain Dagher; Chawki Benkelfat; Marco Leyton
Journal:  J Psychiatry Neurosci       Date:  2016-08       Impact factor: 6.186

Review 4.  From simultaneous to synergistic MR-PET brain imaging: A review of hybrid MR-PET imaging methodologies.

Authors:  Zhaolin Chen; Sharna D Jamadar; Shenpeng Li; Francesco Sforazzini; Jakub Baran; Nicholas Ferris; Nadim Jon Shah; Gary F Egan
Journal:  Hum Brain Mapp       Date:  2018-08-04       Impact factor: 5.038

5.  A comparison of D2 receptor specific binding in obese and normal-weight individuals using PET with (N-[(11)C]methyl)benperidol.

Authors:  Sarah A Eisenstein; Jo Ann V Antenor-Dorsey; Danuta M Gredysa; Jonathan M Koller; Emily C Bihun; Samantha A Ranck; Ana Maria Arbeláez; Samuel Klein; Joel S Perlmutter; Stephen M Moerlein; Kevin J Black; Tamara Hershey
Journal:  Synapse       Date:  2013-05-30       Impact factor: 2.562

Review 6.  Positron emission tomography in Parkinson's disease: insights into impulsivity.

Authors:  Adam J Stark; Daniel O Claassen
Journal:  Int Rev Psychiatry       Date:  2017-12-05

7.  The relationship between excitement symptom severity and extrastriatal dopamine D2/3 receptor availability in patients with schizophrenia: a high-resolution PET study with [18F]fallypride.

Authors:  Yo-Han Joo; Jeong-Hee Kim; Young-Don Son; Hang-Keun Kim; Yeon-Jeong Shin; Sang-Yoon Lee; Jong-Hoon Kim
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-06-16       Impact factor: 5.270

8.  Sex differences in striatal dopamine D2/D3 receptor availability in smokers and non-smokers.

Authors:  Amira K Brown; Mark A Mandelkern; Judah Farahi; Chelsea Robertson; Dara G Ghahremani; Brittany Sumerel; Nathasha Moallem; Edythe D London
Journal:  Int J Neuropsychopharmacol       Date:  2012-01-16       Impact factor: 5.176

9.  Human dopamine receptor D2/D3 availability predicts amygdala reactivity to unpleasant stimuli.

Authors:  Andrea Kobiella; Sabine Vollstädt-Klein; Mira Bühler; Caroline Graf; Hans-Georg Buchholz; Nina Bernow; Igor Y Yakushev; Christian Landvogt; Mathias Schreckenberger; Gerhard Gründer; Peter Bartenstein; Christoph Fehr; Michael N Smolka
Journal:  Hum Brain Mapp       Date:  2010-05       Impact factor: 5.038

10.  PET measurement of changes in D2/D3 dopamine receptor binding in a nonhuman primate during chronic deep brain stimulation of the bed nucleus of the stria terminalis.

Authors:  Nicholas T Vandehey; P Charles Garell; Joseph A Hampel; Dhanabalan Murali; Elizabeth M Smith; Richard Davidson; Alexander K Converse; R Jerry Nickles; Bradley T Christian
Journal:  J Neurosci Methods       Date:  2008-09-09       Impact factor: 2.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.